Nosocomial Infections and Ventilator-Associated Pneumonia in Cancer Patients

  • J. V. DivatiaEmail author
  • Jacob George Pulinilkunnathil
  • Sheila Nainan Myatra
Reference work entry


Nosocomial infections or healthcare-acquired infections are a common cause of increased morbidity and mortality among hospitalized patients. Cancer patients are at an increased risk for these infections due to their immunosuppressed states. Considering these adverse effects on and the socioeconomic burden, efforts should be made to minimize the transmission of these infections and make the hospitals a safer environment. These infection rates can be significantly reduced by the implementing and improving compliance with the “care bundles.”

This chapter will address the common nosocomial infections such as ventilator-associated pneumonia (VAP), catheter-associated urinary tract infections (CAUTI), and surgical site infections (SSI), including preventive strategies and care bundles for the same.


Catheter-associated urinary tract infections Hospital-acquired infections Hospital-acquired pneumonia Nosocomial infections Surgical site infections Ventilator-associated pneumonia 


  1. 1.
    Al-Abdely HM, et al. Impact of the International Nosocomial Infection Control Consortium (INICC)’s multidimensional approach on rates of ventilator-associated pneumonia in intensive care units in 22 hospitals of 14 cities of the Kingdom of Saudi Arabia. J Infect Public Health. 2018;11:677–84. Elsevier. Scholar
  2. 2.
    Al-Mousa HH, et al. Impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach on rates of ventilator-associated pneumonia in intensive care units of two hospitals in Kuwait. J Infect Prev. 2018;19:168–76. Scholar
  3. 3.
    Álvarez-Lerma F, et al. Prevention of ventilator-associated pneumonia. Crit Care Med. 2018;46(2): 181–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Álvarez Lerma F, Sánchez García M, Lorente L, et al. Guidelines for the prevention of ventilator-associated pneumonia and their implementation. The Spanish “Zero-VAP” bundle. Med Intensiva. 2014;38:226–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Azoulay E, et al. The intensive care medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. 2017;43(9):1366–82.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ban KA, et al. American College of Surgeons and surgical infection society: surgical site infection guidelines, 2016 update. J Am Coll Surg. 2017;224(1): 59–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Berríos-Torres SI, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152(8):784–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Borchardt RA, Tzizik D. Update on surgical site infections: the new CDC guidelines. J Am Acad Physician Assist. 2018;31(4):52–4.CrossRefGoogle Scholar
  9. 9.
    Bouadma L, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355:2619–30.CrossRefGoogle Scholar
  11. 11.
    CDC. CDC/NHSN surveillance definitions for specific types of infections. 2018a;(17), pp 1–30.Google Scholar
  12. 12.
    CDC. Urinary tract infection (Catheter-Associated Urinary Tract Infection [CAUTI] and non-catheter-associated urinary tract infection [UTI]) and other urinary system infection [USI]) events. 2018b. Available at: Accessed 14 Jul 2018.
  13. 13.
    Centers for Disease Control. Healthcare-associated Infections (HAI) progress report|HAI|CDC, Centers for Disease Control and Prevention. 2016. Available at: Accessed 13 Jul 2018.
  14. 14.
    Chakravarthy M, et al. The impact of the international nosocomial infection control consortium (INICC) multicenter, multidimensional hand hygiene approach in two cities of India. J Infect Public Health. 2015; 8(2):177–86.CrossRefPubMedGoogle Scholar
  15. 15.
    Chalmers JD, et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):330–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Chenoweth C, Saint S. Preventing catheter-associated urinary tract infections in the intensive care unit. Crit Care Clin. 2013;29(1):19–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Coffin SE, et al. Strategies to prevent ventilatorassociated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29(Suppl. 1):S31–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Cook B. Preventing ventilator associated pneumonia (VAP). Health Protection Scotland. 2016. Accessed 12 Jul 2018.
  19. 19.
    Cornejo-Juárez P, et al. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis. 2015;31:31–4.. Scholar
  20. 20.
    Cornejo-Juárez P, et al. Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients. BMC Infect Dis. BioMed Central. 2016;16:274.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dias Margarida MP, Amaro P. Ventilator-associated pneumonia (VAP) – early and late-onset differences. Eur Respir J. 2013;42(Suppl 57):P2457.Google Scholar
  22. 22.
    Ekren PK, et al. Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society guideline criteria for risk of multidrug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia in the ICU. Am J Respir Crit Care Med. 2018;197(6):826–30.CrossRefPubMedGoogle Scholar
  23. 23.
    El-Saed A, Balkhy HH, Weber DJ. Benchmarking local healthcare-associated infections: available benchmarks and interpretation challenges. J Infect Public Health. 2013;6(5):323–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Garner JS, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control. 2018;46(3):322–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Golia S, K T S, C L V. Microbial profile of early and late onset ventilator associated pneumonia in the intensive care unit of a tertiary care hospital in Bangalore, India. J Clin Diagn Res. JCDR Research & Publications Private Limited. 2013;7(11):2462–6. Scholar
  27. 27.
    Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med. American Thoracic Society. 2005;171(4): 388–416.Google Scholar
  28. 28.
    Gujar M. Colistin for lung infection: an update. J Intensive Care. 2015;22(3):3.CrossRefGoogle Scholar
  29. 29.
    Herer B, et al. Management of nosocomial pneumonia on a medical ward: a comparative study of outcomes and costs of invasive procedures. Clin Microbiol Infect. 2009;15(2):165–72.CrossRefPubMedGoogle Scholar
  30. 30.
    Hooton TM, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Cl Infect Dis: Off Publ Infect Dis Soc Am. 2010;50(5):625–63.CrossRefGoogle Scholar
  31. 31.
    Hunter. Ventilator associated pneumonia. BMJ. 2012;344:e3325.CrossRefPubMedGoogle Scholar
  32. 32.
    Ibn Saied W, Souweine B, Garrouste-Orgeas M, Ruckly S, Darmon M, Bailly S, et al. Respective impact of implementation of prevention strategies, colonization with multiresistant bacteria and antimicrobial use on the risk of early- and late-onset VAP: an analysis of the OUTCOMEREA network. PLoS One. 2017;12(11):e0187791. Scholar
  33. 33.
    IHI. Institute for healthcare improvement: how-to guide: prevent ventilator-associated pneumonia. 2012. Available at: Accessed 12 Jul 2018.
  34. 34.
    Institute for Healthcare Improvement: Evidence-Based Care Bundles n.d.. Available at: Accessed 17 Jul 2018.
  35. 35.
    Institute For Healthcare Improvement, I. Institute for healthcare improvement: how-to guide: prevent ventilator-Associated pneumonia. 2012. Available at: Accessed 17 Jul 2018.
  36. 36.
    Jamal J-A, Abdul-Ain M-H, Lipman J, Roberts JA. Defining antibiotic dosing in lung infections. Clin Pulm Med. 2013;20(3):121–8.CrossRefGoogle Scholar
  37. 37.
    Jones BE, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006–2010. Clin Infect Dis. 2015;61(9):1403–10.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Swanson JM, Wells DL. Empirical antibiotic therapy for ventilator-associated pneumonia. Antibiotics (Basel). 2013;2(3):339–51.CrossRefGoogle Scholar
  39. 39.
    Kalanuria AA, et al. Ventilator-associated pneumonia in the ICU. Crit care. BioMed Central. 2014;18(2):208.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kalil AC, et al. Management of Adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed. 2015;509–514
  42. 42.
    Khan HA, Baig FK, Mehboob R. Nosocomial infections: epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed. Elsevier B.V. 2017;7(5):478–82. Scholar
  43. 43.
    Khan P, Divatia JV. Severe sepsis bundles. Indian J Crit Care Med. 2010;14(1):8–13.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Klavs I, et al. Prevalence of and risk factors for hospital-acquired infections in Slovenia-results of the first national survey, 2001. J Hosp Infect. 2003; 54(2):149–57.CrossRefPubMedGoogle Scholar
  45. 45.
    Klavs I, et al. The prevalence of and risk factors for healthcare-associated infections in Slovenia: results of the second national survey. Zdravstveno varstvo. 2016;55(4):239–47.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Klevens RM, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep (Washington, DC: 1974). 2007;122(2): 160–6.CrossRefGoogle Scholar
  47. 47.
    Klompas M, et al. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation. JAMA Intern Med. 2014;174(5):751.CrossRefPubMedGoogle Scholar
  48. 48.
    Köves B, et al. Benefits and harms of treatment of asymptomatic bacteriuria: A systematic review and meta-analysis by the European Association of Urology urological infection guidelines panel. Eur Urol. 2017;72(6):865–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Kuti EL, Patel AA, Coleman C. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1): 91–100.CrossRefPubMedGoogle Scholar
  50. 50.
    Langer M, Cigada M, Mandelli M, Mosconi P, G T. Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med. 1987;13:342–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Iannella HA, Luna CM. Treatment failure in ventilator associated pneumonia. Curr Respir Med Rev. 2012;8:239–44.CrossRefGoogle Scholar
  52. 52.
    Mao Z, et al. Subglottic secretion suction for preventing ventilator-associated pneumonia: an updated meta-analysis and trial sequential analysis. Crit Care (London). 2016;20(1):353. Scholar
  53. 53.
    Kollef MH, Afessa B, Antonio Anzueto M, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia the NASCENT randomized trial. JAMA. 2008;300(7):805–13.CrossRefPubMedGoogle Scholar
  54. 54.
    Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. Curr Opin Crit Care. 2018;24(5):347–52.CrossRefPubMedGoogle Scholar
  55. 55.
    Mehta Y, et al. Guidelines for prevention of hospital acquired infections. Indian J Crit Care Med. 2014;18(3):149–63.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Mehta Y, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 21 adult intensive-care units from 10 cities in India: findings of the International Nosocomial Infection Control Consortium (INICC). Epidemiol Infect. 2013;141(12):2483–91. Scholar
  57. 57.
    Melsen WG, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665–71.CrossRefPubMedGoogle Scholar
  58. 58.
    Muscedere J, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care. 2008;23(1): 126–37.CrossRefPubMedGoogle Scholar
  59. 59.
    Niederman MS. Antibiotic treatment of hospital-acquired pneumonia. Curr Opin Crit Care. 2018;24(5):353–60.CrossRefPubMedGoogle Scholar
  60. 60.
    Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1995;152:1982–91.CrossRefPubMedGoogle Scholar
  61. 61.
    Pappas PG, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.CrossRefGoogle Scholar
  62. 62.
    Di Pasquale M, et al. Non-intensive care unit acquired pneumonia: a new clinical entity? Int J Mol Sci. 2016;17(3):287.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Pickard R, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet (London). 2012;380(9857):1927–35.CrossRefGoogle Scholar
  64. 64.
    Ramirez J, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756–62.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Ranzani OT, De Pascale G, Park M. Diagnosis of nonventilated hospital-acquired pneumonia. Curr Opin Crit Care. 2018;24(5):339–46.CrossRefPubMedGoogle Scholar
  66. 66.
    Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med. 1999; 27:887–92.CrossRefPubMedGoogle Scholar
  67. 67.
    Rosenthal VD, et al. Surgical site infections, international nosocomial infection control consortium (INICC) report, data summary of 30 countries, 2005–2010. Infect Control Hosp Epidemiol. 2013; 34(06):597–604.CrossRefPubMedGoogle Scholar
  68. 68.
    Rosenthal VD, et al. International nosocomial infection control consortium report, data summary of 50 countries for 2010–2015: device-associated module. Am J Infect Control. 2016;44(12):1495–504.CrossRefPubMedGoogle Scholar
  69. 69.
    Rosenthal VD, et al. Impact of the international nosocomial infection control consortium’s multidimensional approach on rates of ventilator-associated pneumonia in 14 intensive care units in 11 hospitals of 5 cities within Argentina. Am J Infect Control. 2018;46(6):674–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Saint S, et al. A program to prevent catheter-associated urinary tract infection in acute care. N Engl J Med. Massachusetts Medical Society. 2016;374(22):2111–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Shah PS, et al. Controlling antimicrobial use and decreasing microbiological laboratory tests for urinary tract infections in spinal-cord-injury patients with chronic indwelling catheters. Am J Health Syst Pharm. 2005;62(1):74.CrossRefPubMedGoogle Scholar
  72. 72.
    Shalini S, et al. Impact and effect of nosocomial infections: a review. Res J Pharm, Biol Chem Sci. 2015;6(1):947–51.Google Scholar
  73. 73.
    Silverman JA, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149–52.CrossRefPubMedGoogle Scholar
  74. 74.
    Singer M. Biomarkers in sepsis. Curr Opin Pulm Med. 2013;19(3):305–9.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Sole Violan J, Fernandez JA, Benitez AB, et al. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit Care Med. 2000;28:2737–41.CrossRefPubMedGoogle Scholar
  76. 76.
    Surbatovic M, et al. Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma. Mediat Inflamm. Hindawi Limited. 2013; 2013:362793. Scholar
  77. 77.
    Tariq A, Ali H, Zafar F, Sial AA, Hameed K, et al. A systemic review on surgical site infections: classification, risk factors, treatment complexities, economical and clinical scenarios. J Bioequivalence Bioavailab. 2017;9:336–40. Scholar
  78. 78.
    Torres A, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50(3):1700582.CrossRefPubMedGoogle Scholar
  79. 79.
    Torres A, et al. Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Res. 2018;4(2):00028–2018. Scholar
  80. 80.
    Umscheid CA, Mitchell MD, Doshi JA, et al. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32(2):101–14.CrossRefPubMedGoogle Scholar
  81. 81.
    Valcke Y, Pauwels R, Van der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur Respir J. 1990;3(6): 715–22.Google Scholar
  82. 82.
    Vincent J, Rello J, Marshall J, Silva E, Anzueto A, Martin C, Moreno R, Lipman J, Gomersall C, Sakr Y, R. K. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.CrossRefGoogle Scholar
  83. 83.
    Vincent J-L, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA. 1995;274(8):639–44.CrossRefPubMedGoogle Scholar
  84. 84.
    Wacker C, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426–35.CrossRefPubMedGoogle Scholar
  85. 85.
    Wang Y, et al. National Trends in patient safety for four common conditions, 2005–2011. N Engl J Med. 2014;370(4):341–51.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest. 1999;115(3):34S–41S.CrossRefPubMedGoogle Scholar
  87. 87.
    Weigelt JA, Lipsky BA, Tabak YP, et al. Surgical site infections: control., causative pathogens and associated outcomes. Am J Infect. n.d.;38(2):112–20.Google Scholar
  88. 88.
    WHO|My 5 Moments for Hand Hygiene. WHO. World health organization. 2017. Available at: Accessed 17 Jul 2018.
  89. 89.
    Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis. 2010;51(S(1)):S131–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • J. V. Divatia
    • 1
    Email author
  • Jacob George Pulinilkunnathil
    • 1
  • Sheila Nainan Myatra
    • 1
  1. 1.Department of Anaesthesia, Critical Care and PainTata Memorial Hospital, Homi Bhabha National InstituteMumbaiIndia

Personalised recommendations